Goldman Sachs Group Inc Nektar Therapeutics Call Options Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
Call Options
2 transactions
Others Institutions Holding NKTR
# of Institutions
128Shares Held
111MCall Options Held
150KPut Options Held
4K-
Deep Track Capital, LP Greenwich, CT18.4MShares$21.5 Million0.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$14.1 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA7.57MShares$8.86 Million0.02% of portfolio
-
Primecap Management CO Pasadena, CA6.97MShares$8.15 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.88MShares$6.88 Million0.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $219M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...